-+ 0.00%
-+ 0.00%
-+ 0.00%
Changes in Hong Kong stocks | Cornerstone Pharmaceutical-B (02616) rose nearly 6% at the end of the session. The company and Kimia reached a cooperation to lead the clinical trial of a DDR pathway solid tumor drug candidate
Share
Listen to the news

The Zhitong Finance App learned that Cornerstone Pharmaceutical-B (02616) rose nearly 6% at the end of the session. As of press release, it rose 5.92% to HK$5.46, with a turnover of HK$28.01 million.

According to the news, recently, Cornerstone Pharmaceuticals announced that it has reached a cooperation with Kimia. The two sides will jointly advance the clinical development of a solid tumor drug candidate with similar pioneering potential and targeting the DNA damage response (DDR) pathway critical to solid tumor survival. Cornerstone Pharmaceuticals will share the global commercialization value of this first-of-its-kind drug through milestone payments and sales shares.

According to the details of the cooperation, Cornerstone Pharmaceuticals will use its full-chain clinical development and registration expertise in the field of oncology to lead the phase I clinical development of this candidate drug in China and Australia. Kimia will be responsible for providing clinical use of this drug candidate, scientific guidance, coordination of product-related registration matters, and development support agreed in other agreements to form a joint development model with complementary advantages.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending